Faculty, Staff and Student Publications

Language

English

Publication Date

3-1-2026

Journal

Physics and Imaging in Radiation Oncology

DOI

10.1016/j.phro.2026.100941

PMID

41858749

PMCID

PMC12997195

PubMedCentral® Posted Date

3-3-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Purpose: To evaluate the impact of intra- and interfractional motion on dose distribution and clinical outcome in prostate magnetic resonance (MR)-guided adaptive radiotherapy.

Methods: Seventy-six patients were treated with five-fraction stereotactic radiotherapy on a 1.5 T MR linear accelerator. Cine MR images were acquired during treatment and exported to a motion monitoring research package, to generate motion traces in the anterior-posterior (AP), superior-inferior (SI) and left-right (LR) directions. Planned dose distributions were shifted according to motion trace to reconstruct intrafraction motion-blurred dose. Intrafraction motion-blurred doses were deformably registered to fraction one motion-blurred dose to obtain interfraction accumulated dose. The impact of motion on prostate, bladder, rectal and urethral dose-volume parameters were assessed. Correlation between patients experiencing prolonged motion > 3 mm and urinary adverse events was evaluated.

Results: The average intrafraction prostate motion was -0.0 ± 0.2 mm (LR), 0.3 ± 0.5 mm (AP), and -0.3 ± 0.6 mm (SI). Intrafraction motions were associated with dose-volume parameter deviations up to 2.5 Gy. During 24 months of follow-up, 3 patients experienced ≥ Grade 2 acute adverse events, and 4 patients reported ≥ Grade 2 long term adverse events evaluated with common terminology criteria for adverse events. All patients with clinically significant urinary adverse events experienced prolonged large intrafraction motion > 3 mm. Interfraction accumulated motion-blurred dose demonstrated substantial interpatient variabilities for bladder, rectum and urethra.

Conclusion: Prolonged intrafraction motion > 3 mm may result in dose difference and clinically significant urinary adverse events. However, combined intra- and interfraction motion might average out fraction-specific variations.

Keywords

Prostate cancer, Intrafraction motion, Dose-blurring, Urinary adverse events

Published Open-Access

yes

ga1.jpg (44 kB)
Graphical Abstract

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.